🇺🇸 Paclitaxel (PTX) in United States

8 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 23 April 2025 – 23 April 2026
• Total reports: 8

Most-reported reactions

1. Blood Pressure Decreased — 1 report (12.5%)
2. Death — 1 report (12.5%)
3. Drug Hypersensitivity — 1 report (12.5%)
4. Malignant Neoplasm Progression — 1 report (12.5%)
5. Peritonitis — 1 report (12.5%)
6. Rash — 1 report (12.5%)
7. Skin Disorder — 1 report (12.5%)
8. Stevens-Johnson Syndrome — 1 report (12.5%)

Source database →

Frequently asked questions

Is Paclitaxel (PTX) approved in United States?

Paclitaxel (PTX) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Paclitaxel (PTX) in United States?

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections is the originator. The local marketing authorisation holder may differ — check the official source linked above.